Drug Profile
Research programme: multiple sclerosis therapeutics - Amgen
Alternative Names: AMG 247; AMG 369Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amgen; EPIX Pharmaceuticals
- Developer Amgen
- Class Benzofurans
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA